Clinical Scorecard: Comparative Effectiveness of Cognitive Behavioral Therapy and Bright Light Treatment for Insomnia in Women with Breast Cancer Undergoing Chemotherapy
At a Glance
Category
Detail
Condition
Insomnia and cancer-related fatigue in women with breast cancer
Key Mechanisms
Cognitive Behavioral Therapy for Insomnia (CBT-I) and Bright Light Therapy (BLT) targeting sleep improvement and fatigue reduction
Target Population
Women aged 18 years or older with breast cancer undergoing chemotherapy
Care Setting
Multicenter clinical trial in Australian hospitals
Key Highlights
Insomnia affects 62% and moderate to severe fatigue affects 43% of women with breast cancer.
Chemotherapy increases the prevalence of insomnia symptoms to 70%.
CBT-I is the first-line treatment for insomnia, including among cancer patients.
BLT may improve sleep and reduce fatigue by targeting circadian rhythms.
The study examines the efficacy of CBT-I and BLT during chemotherapy.
Guideline-Based Recommendations
Diagnosis
Eligibility includes a diagnosis of breast cancer at any stage and ongoing systemic chemotherapy.
Management
CBT-I and BLT are evaluated as interventions for insomnia and fatigue.
Monitoring & Follow-up
Participants' insomnia symptoms and fatigue levels are monitored throughout the trial.
Risks
Exclusion criteria include severe psychiatric disorders and daily sleep-medication use.
Patient & Prescribing Data
Women with breast cancer undergoing chemotherapy
CBT-I and BLT may be effective interventions for managing insomnia and fatigue.
Clinical Best Practices
Consider CBT-I as a first-line treatment for insomnia in cancer patients.
Utilize BLT to address circadian rhythm misalignment in patients experiencing fatigue.
by Trang Thuy Do, Jordan Maccora, Rebecca Wallace, Veronica Aedo-Lopez, Marliese Alexander, Sonia Ancoli-Israel, Bei Bei, Robert Blum, Frances Boyle, Daphne Day, Justine Diggens, Prudence A. Francis, Maria Ftanou, Sheila N. Garland, Alysia Kepert, Duncan Mortimer, Andrew J. K. Phillips, Sharad Sharma, Lesley Stafford, Michelle White, Joshua F. Wiley
he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
